Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial glycine transporter (SLC25A38) is a member of the solute carrier (SLC25) family located in the inner mitochondrial membrane. Its primary physiological function is to import glycine into mitochondria, an essential step for heme biosynthesis, since glycine is a substrate for δ-aminolevulinic acid (ALA) synthesis—the first and rate-limiting step in the heme pathway. Mutations in SLC25A38 are the leading genetic cause of autosomal recessive congenital sideroblastic anemia, a severe, transfusion-dependent disease associated with iron overload. SLC25A38 is also emerging as a prognostic biomarker in certain cancers, with altered expression correlating with disease progression in uveal melanoma and possibly other tumors. There are currently no direct small-molecule or biologic drugs targeting SLC25A38; the main therapeutic approaches aim to bypass the defect by supplementing glycine, ALA, or folate to restore heme synthesis.
Glycine or ALA supplementation aims to overcome the block in heme synthesis by providing substrates downstream of the defective transporter.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial glycine transporter (SLC25A38).